WEO CRC SC Meeting. Barcelona, Spain October 23, 2015
|
|
- Andrea Hampton
- 5 years ago
- Views:
Transcription
1 WEO CRC SC Meeting Barcelona, Spain October 23, 2015
2 THE HEMOGLOBIN CONCENTRATION IN A NEGATIVE RESULT AS A PREDICTOR FOR ADVANCED NEOPLASIA Isabel Portillo, Eunare Arana-Arri, Isabel Idigoras, Lorea Martínez-Indart. Colorectal Cancer Screening Programme. Basque Country. mariaisabel.portillovillares@osakidetza.eus
3 No conflicts of interest
4 THE BASQUE COUNTRY PROGRAMME Coverage Objective: To decrease CRC incidence and mortality by detection and treatment of premalignant and malignant lesions First round Second round Third round
5 THE BASQUE COUNTRY PROGRAMME STRATEGY POPULATION BASED year-olds (586,700 people) FIT biennial. Cut-off 20µg Hb/g OC-Sensor from 2010 Colonoscopy under sedation as confirmatory test Information system linked with medical database and cancer registries Primary Care Involved Centralized coordination MAIN RESULTS TOTAL INVITED 958,450 PARTICIPATION RATE 68.5% POSITIVE RATE 6.2% COLONOSCOPY UPTAKE 93.7% CCR DETECTION RATE 3.4 AA DETECTION RATE 23.3 AN DETECTION RATE 26.7 PPV CCR 5.4% PPV AA 37.5% PPV AN 42.9%
6 HYPOTHESIS There is a relationship between the Hb concentration in negative cases and lesion detected in successive rounds A pattern of bleeding could predict the lesion detected after a negative result in successive rounds
7 OBJECTIVES To know the association between Hb concentration in positives cases with an Advanced Neoplasia detected and their previous negative results. To know the pattern of this association by sex, age group, type of lesion compared with no adenomatous lesion. To know the pattern of this association in CRC by localization and stage.
8 METHODS 2 GROUPS 1. Participants who had three rounds with two previous negative results and a lesion detected in the third round 2. Participants who had a previous negative result and a lesion detected in successive round Lesions: Colorectal Cancer, Advanced Adenoma, Advanced Neoplasia (CRC+AA) and Low Risk Adenoma. No lesions: negative FIT and positive FIT and negative colonoscopy for CRC, adenoma or other bleeding colonic pathology. Faecal Hb concentrations differences between lesion detected and previous negative result were analyzed (Mann-Whitney test) Logistic regression: to analyze the association of Hb concentration with the diagnosis of Advanced Neoplasia
9 LIMITATIONS Previous lesion before the debut as positive cases are unknown (only in positive cases the colonoscopy was performed) Comparison in irregular attendees was not analyzed Other risk factors such as lifestyle, morbidity and deprivation were not taken into consideration for this study
10 µg Hb/g µg Hb/g MAIN RESULTS GROUP 1 GROUP 2 First Round 45,185 NEGATIVE FIT Previous Round 178,307 NEGATIVE FIT Second Round Third Round 45,185 NEGATIVE FIT POSITIVE FIT 43,016 NEGATIVE FIT Second Round 10,772 POSITIVE FIT 167,535 NEGATIVE FIT 72 CRC 654 AA 726 AN 367 LRA 911 NEGATIVE COLONOSCOPY 417 CRC 3,260 AA 3,677 AN 1,799 LRA 3,640 NEGATIVE COLONOSCOPY RISK OF A COLONIC ADENOMA/CRC AFTER A PREVIOUS NEGATIVE RESULT Interval of 4 years Interval of 2 years CRC AA AN LRA Group 1 CRC AA AN LRA Group 2
11 µd Hb/g µd Hb/g µd Hb/g GROUP 1: DIFFERENCES IN HB CONCENTRATION BETWEEN THIRD ROUND AND FIRST ROUND BY LESION BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) LESIONS IN ROUND 3 CRC (72) < <0.001 AA (654) < <0.001 AN (726) < <0.001 LRA (367) < <0.001 NO LESIONS IN ROUND 3 (43,733) TRENDS IN HB CONCENTRATION BY LESION CRC no in 3 round CRC yes in 3 round AA no in 3 round AA yes in 3 round AN no in 3 round AN yes in 3 round round 1 round 2 round 3 round 1 round 2 round 3 round 1 round 2 round 3
12 µd Hb/g µd Hb/g GROUP 1: DIFFERENCES IN HB CONCENTRATION BETWEEN THIRD ROUND AND FIRST ROUND BY LESION WOMEN Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) MEN Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) LESIONS IN ROUND 3 NO LESIONS IN ROUND 3 (24,995) CRC (27) AA (217) AN (244) LRA (149) < < < < < < < LESIONS IN ROUND 3 CRC (45) AA (437) AN (482) LRA (218) NO LESIONS IN ROUND 3 (18,738) < < < < < < < < TRENDS IN HB CONCENTRATION IN ADVANCED NEOPLASIA WOMEN AN no in 3 round AN yes in 3 round MEN AN no in 3 round AN yes in 3 round round 1 round 2 round 3 round 1 round 2 round 3
13 GROUP 1: HB CONCENTRATION BY RANGES IN FIRST ROUND P< P< P< BOTH SEX HB (µg Hb/g) IN ROUND LESIONS IN CRC (72) 84.7% 6.9% 6 8.3% ROUND 3 AA (647) 72.5% 15.5% 12.1% AN (719) 73.7% 14.6% 11.7% LR (364) 83.8% 7.1% 9.1% NO LESIONS IN ROUND 3 (43,652) 94.3% 3.5% 2.3% WOMEN HB (µg Hb/g) IN ROUND LESIONS IN CRC (27) 85.2% 7.4% 7.4% ROUND 3 AA (214) 72.9% 15.4% 11.7% AN (241) 74.3% 14.5% 11.2% LR (149) 86.6% 7.4% 6.0% NO LESIONS IN ROUND 3 (24,948) 95.1% 3.0% 1.9% MEN HB (µg Hb/g) IN ROUND LESIONS IN CRC (45) 84.4% 6.7% 8.9% ROUND 3 AA (433) 72.3% 15.5% 12.2% AN (478) 73.4% 14.6% 11.9% LR (215) 81.9% 7.0% 11.2% NO LESIONS IN ROUND 3 (18,704) 93.3% 4% 2.7%
14 GROUP 1: DIFFERENCES IN HB CONCENTRATION BY CRC LOCALIZATION AND STAGE BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) CRC RIGHT COLON (16) LEFT COLON (49) BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) CRC STAGE I-II (41) STAGE III-IV (28)
15 GROUP 2: DIFFERENCES IN HB CONCENTRATION BETWEEN SUCESSIVE AND PREVIOUS ROUND BY LESION BOTH SEX Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN CRC ROUND 2 (417) AA (3,260) AN (3,677) LRA (1,799) NO LESIONS IN ROUND 2 (171,175) < < < < < < < <
16 GROUP 2: DIFFERENCES IN HB CONCENTRATION BETWEEN SUCESSIVE AND PREVIOUS ROUND BY LESION AND SEX WOMEN Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN ROUND 2 CRC (147) < <0.001 AA (1,017) AN (1,164) NO LESIONS IN ROUND 2 (94,986) < < < <0.001 LRA (700) < < MEN Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN ROUND 2 NO LESIONS IN ROUND 2 (76,189) CRC (270) < <0.001 AA (2,228) AN (2,498) LRA (1,099) < < < < < <
17 GROUP 2: HB CONCENTRATION BY RANGES IN FIRST ROUND P< BOTH SEX HB (µg Hb/g) IN ROUND LESION IN CRC (417) 66.4% 14.9% 18.7% ROUND 2 AA (3,240) 66.5% 15.1% 18.4% AN (3,657) 66.5% 15.1% 18.4% LR (1,798) 80.1% 10.5% 9.5% NO LESION ROUND 2 (169,782) 93.9% 3.8% 2.3% P< P< WOMEN HB (µg Hb/g) IN ROUND 1 LESION IN ROUND CRC (147) 70.7% 12.9% 16.3% AA (1,019) 69.4% 13.0% 17.7% AN (1,166) 69.6% 13.0% 17.5% LR (711) 81.2% 11.3% 7.65% NO LESION IN ROUND 2 (94,920) 94.5% 3.6% 2.0% MEN HB (µg Hb/g) IN ROUND LESION IN ROUND 2 CRC (270) 64.1% 15.9% 20.0% AA (2,234) 65.6% 16.7% 17.8% AN (2,504) 65.4% 16.6% 18.0% LR (1,103) 79.1% 9.6% 11.3% NO LESION IN ROUND 2 (76,139) 92.7% 4.5% 2.8%
18 GROUP 2: DIFFERENCES IN HB CONCENTRATION BY CRC LOCALIZATION AND STAGE Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) BOTH SEX CRC RIGHT COLON (86) LEFT COLON (273) BOTH SEX Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) CRC STAGE I-II (252) STAGE III-IV (115)
19 MESSAGE TO TAKE HOME There is no association between previous concentration of Hb and lesion detected in successive rounds. No special pattern was found that allows us to predict the development of Advanced Neoplasia after a negative result. The OR prediction found even their statistical significance in most cases has no clinical relevance No relevant differences were found by sex, age group, CRC stage and localization Intermittent bleeding could be the most important pattern Participation in screening is the most important key to detect lesions Previous bleeding (over 10µ Hb/g faeces) should be carefully considered In order to balance benefits and risks in Screening Programmes
Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE
Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds Carlo SENORE Possible conflicts of interest None related to the presentation Carlo Senore AIMS To estimate
More informationWEO CRC SC Meeting. Vienna, Austria October 14, 2016
WEO CRC SC Meeting Vienna, Austria October 14, 216 Possibleconflictsofinterest The Bowel Health Service receives material support from Eiken Chemical Company. Erin Symonds FIT positivity rate is highest
More informationFaecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients
Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Caroline Addison NE BCSP Hub Director and Consultant Clinical Scientist What is FIT Type of Faecal Occult Blood test Designed
More informationFriday, 23 October 2015: 10:15 12:00 * * * * *
Barcelona 2015 8 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 23 October 2015: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University
More informationScreening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee
Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects
More informationRisk scoring incorporating FIT in triage of symptomatic patients
Risk scoring incorporating FIT in triage of symptomatic patients Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible conflicts of interest None Background Symptoms
More informationPractical challenges in establishing and running the Czech national colorectal cancer screening programme
Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha 1. lékařská fakulta Univerzity Karlovy Interní klinika Practical challenges in establishing and running the Czech national colorectal cancer
More informationComparison of FIT performance in screening programs. Carlo Senore
Comparison of FIT performance in screening programs Possible conflicts of interest None related to the presentation Background Several FIT kits are now available Various FIT brands use a variety of sampling
More informationFriday, 17 October 2014: 08:30 11:30 * * * * *
Vienna 2014 6 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 17 October 2014: 08:30 11:30 MEETING REPORT * * * * * Jim Allison, University
More informationMeasuring performance and quality indicators of CRC screening
Measuring performance and quality indicators of CRC screening Ondřej MÁJEK Institute of Biostatistics and Analyses, Masaryk University Institute of Biostatistics and Analyses, Masaryk University, Brno
More informationGlobal colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne
Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University. 2014 WCC, Melbourne Outline WHO criteria to justify screening Appropriateness: Global variation in incidence
More informationFriday, 15 May 2015: 10:00 12:00 * * * * *
Washington 2015 7 th Meeting of the Expert Working Group (EWG) FIT for Screening Friday, 15 May 2015: 10:00 12:00 MEETING REPORT * * * * * Expert Working Group (EWG) founding members: Jim Allison, University
More informationNHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.
NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. Sue Moss, Christopher Mathews Centre for Cancer Prevention, Wolfson Institute, Queen Mary University
More informationImplementing of Population-based FOBT Screening
Implementing of Population-based FOBT Screening gfobt to FIT Experience from England Prof Stephen P. Halloran Guaiac FOBt Haem 2H 2 O 2 = 2H 2 0 + O 2 Oxidised guaiaconic acid is blue Biennial Bowel Cancer
More informationThe Dutch bowel cancer screening program Relevant lessions for Ontario
The Dutch bowel cancer screening program Relevant lessions for Ontario Ernst J Kuipers Erasmus MC University Medical Center Rotterdam - The Netherlands 1 Ismar Boas (1858 1938) Colorectal cancer screening
More informationColorectal cancer screening in England
Colorectal cancer screening in England critical analysis Prof Stephen P. Halloran Participation Rate 57% All Screens (1.9% +ve) 52% Prevalent 1 st Screen (age 60 years) 36% Prevalent Screen (2.2% +ve)
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationA TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test
A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE Stool DNA test THE NEW NON-INVASIVE SCREENING TEST FOR COLORECTAL CANCER Sensitive Clinically proven 1 Easy to use FDA approved COLOGUARD
More informationBowel cancer screening and prevention
Bowel cancer screening and prevention Cancer Incidence and Mortality Victoria 2012 Number 6000 5000 4000 3000 2000 Incidences = 29,387 Mortality = 10,780 Incidence Mortality 1000 0 Prostate Breast Bowel
More informationWEO CRC SC Meeting. Barcelona, Spain October 23, 2015
WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,
More informationCost-effectiveness of adenoma surveillance - the Dutch guidelines -
Cost-effectiveness of adenoma surveillance - the Dutch guidelines - WEO working group adenoma surveillance 20 May, 2016 Iris Lansdorp-Vogelaar, PhD On behalf of the SAP study-group Introduction Adenoma
More informationMeasure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care
Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationProf Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT
Prof Stephen P. Halloran Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT World Top 20 Cancers Men Incidence & Mortality (2012) Women World Colorectal Cancer 3 rd commonest cancer 4
More informationChallenges for Colorectal Cancer Screening
Challenges for Colorectal Cancer Screening a Biomarker with No Standards! Prof. Emeritus Stephen P. Halloran University of Surrey W. Europe Top 20 Cancers Men Incidence & Mortality (2012) Women World -
More informationBowel Cancer Screening Exploiting science brings better medicine
Camberley & District Bowel Cancer Screening Exploiting science brings better medicine Prof Stephen P. Halloran World - All Cancers Men Incidence & Mortality (2012) Women Incidence Mortality GLOBOCAN 2012
More informationFIT Overview. Objectives 6/23/2014
ADDS 2014: Plenary 2 FIT Update Clarence Wong, MD FRCPC Associate Professor of Medicine, University of Alberta Provincial Medical Lead, Alberta Colorectal Cancer Screening Program 1 Objectives After this
More informationPerformance of Colorectal cancer screening in the European Union Member States Data from the second European screening report
Performance of Colorectal cancer screening in the European Union Member States Data from the second European screening report 1 Basu P 2, Anttila A 3, Ponti A 1, Tomatis M 1, Vale DB 4, Ronco G 1, Soerjomataram
More informationIARC Handbook Volume 17: Colorectal Cancer Screening. Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17
IARC Handbook Volume 17: Colorectal Cancer Screening Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17 IARC Handbooks of Cancer Prevention An important part of cancer prevention
More informationFIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland
FIT - A Tale of Two Settings Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible Conflicts of Interest Consultant: Kyowa, Tokyo, Japan Consultant:
More informationAn Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018
An Update on the Bowel Cancer Screening Programme Natasha Djedovic, London Hub Director 17 th September 2018 NHS Bowel Cancer Screening Programme 2006: 60-69 yr old men & women offered guaiac Faecal Occult
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationEfficacy, effectiveness, quality: sources of data
Efficacy, effectiveness, quality: sources of data Ondřej MÁJEK Institute of Biostatistics and Analyses, Masaryk University Institute of Biostatistics and Analyses, Masaryk University, Brno Key Questions
More informationWhy FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening
Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening Prof. Stephen Halloran Royal Surrey County Hospital NHS Cancer Screening Programme University of Surrey gfobt Guaiacum Officinale
More informationBowel Cancer Screening
Bowel Cancer Screening Dr John Hancock FRCP Consultant Gastroenterologist University Hospital of North Tees Outline Background Current bowel cancer screening programme Tees Screening Centre Future Flexi
More informationOptimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial
Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial J. Tinmouth, N.N. Baxter, L.F. Paszat, E. Randell, M. Serenity, R. Sutradhar, L. Rabeneck Conflicts of
More informationPopulation-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
Arana-Arri et al. BMC Cancer (2017) 17:577 DOI 10.1186/s12885-017-3555-3 RESEARCH ARTICLE Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin
More informationColorectal cancer screening
26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant
More informationCOLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE
COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE Brno, 29 May 2015: For the fourth time in a row, the second largest city of the Czech Republic will host the European Colorectal
More informationNorth West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist
Faecal Occult Blood testing Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Background Guidelines for colorectal cancer detection Tests available to detect occult blood in faeces
More informationScreening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences
Original Article Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences J Med Screen 20(3) 125 148! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
More informationEvaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model
Idigoras et al. BMC Public Health (2018)18:78 DOI 10.1186/s12889-017-4639-3 RESEARCH ARTICLE Open Access Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness
More informationUniversity of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016
University of Dundee Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited Digby, Jayne; Fraser, Callum G.; Carey, Francis A.; Lang,
More informationColonoscopy Quality Data 2017
Colonoscopy Quality Data Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. According to the American Cancer Society, in
More informationQuantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc.
Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. European Digestive Cancer Days, Prague - 26. September 2017 QUANTITATIVE FIT
More informationFriday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * *
San Diego 2016 9 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University
More informationEU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme. Jožica Maučec Zakotnik
EU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme Jožica Maučec Zakotnik EU guidelines Luxembourg 2010 EU guidelines - chapters
More informationCzech CRC screening program at the point of switch to the population based design
Military University Hospital First Medical Faculty of Charles University Department of Gastroenterology Czech CRC screening program at the point of switch to the population based design M. Zavoral, S.
More informationColorectal cancer screening: strategies to select populations with moderate risk for disease
1130-0108/2009/101/12/855-860 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2009 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 101. N. 12, pp. 855-860, 2009 Colorectal cancer screening:
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical
More informationResults from 2.6 million invitations between : 54% overall uptake (von Wagner et al., 2011)
TRICCS: Text-message Reminders in Colorectal Cancer Screening Research Department of Behavioural Science and Health University College London Christian von Wagner (c.wagner@ucl.ac.uk ) Background Colorectal
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationQuality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?
Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.
More informationPerformance targets for lesion detection in surveillance
Performance targets for lesion detection in surveillance WEO CRC Meeting 2018, Washington DC Uri Ladabaum, M.D., M.S. Professor of Medicine; Director, GI Cancer Prevention Division of Gastroenterology
More informationCOLON CANCER SCREENING: AN UPDATE
Overview COLON CANCER SCREENING: AN UPDATE Siddharth Verma, DO, JD Rutgers New Jersey Medical School Background Screening Updates in Specific Populations African Americans CRC in the younger age USPSTF
More informationFecal immunochemical testing results and characteristics of colonic lesions
Original article 111 Fecal immunochemical testing results and characteristics of colonic lesions Authors Sascha C. van Doorn 1, Inge Stegeman 2, An K. Stroobants 3, Marco W. Mundt 4, Thomas R. de Wijkerslooth
More informationEarly detection and screening for colorectal neoplasia
Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2018
More informationWhat I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance
WEO SC EWG FIT for Screening Head to Head Comparisons of Different FITs Thomas F. Imperiale, MD Indiana University Medical Center WEO SC DDW San Diego, CA May 20, 2016 What I ll discuss Technical / clinical
More informationDiagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30
Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 NICE 2018. All rights reserved. Subject
More informationColorectal Cancer Prevention Hospital Universitário São Paulo University
Colorectal Cancer Prevention Hospital Universitário São Paulo University GENERAL STRATEGY AND RESULTS Dr Luis Masúo Maruta Dr. Marcelo Rodrigues Borba Hospital Universitário São Paulo University Hospital
More informationC olorectal cancer (CRC) is one of the leading causes of
1329 COLON Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure
More informationCOLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.
The West London Medical Journal 2009 Vol No 1 pp 23-31 COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah
More informationColorectal Cancer Screening and Surveillance
1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal
More informationPopulation-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M.
UvA-DARE (Digital Academic Repository) Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M. Link to publication Citation for published version
More informationDr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance
FIT for symptomatic patients Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance AIMS Review National advice Consider
More informationSarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction
Canadian Gastroenterology and Hepatology Volume 2016, Article ID 5914048, 5 pages http://dx.doi.org/10.1155/2016/5914048 Research Article Comparison of One versus Two Fecal Immunochemical Tests in the
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process
Measure. #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2017
More informationEarlier stages of colorectal cancer detected with immunochemical faecal occult blood tests
O R I G I N A L A R T I C L E Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests L.G.M. van Rossum 1*, A.F. van Rijn 2, I.P. van Munster 3, J.B.M.J. Jansen 1, P.
More informationScreening di Popolazione. del Cancro Colorettale. C. Hassan
Screening di Popolazione del Cancro Colorettale C. Hassan The Present 1. Organized screening program - Active invitation (less inequality) - Rapid coverage of the target population (2 yrs) - Quality Assurance
More informationPrimary care at the forefront of colorectal cancer screening
Primary care at the forefront of colorectal cancer screening Presentation by Bohumil Seifert Department of General Practice, 1st Faculy of Medicine, Charles University in Prague 04/05/2012 Introduction
More informationPathology in Slovenian CRC screening programme:
Pathology in Slovenian CRC screening programme: Findings, organisation and quality assurance Snježana Frković Grazio University Medical Center Ljubljana, Slovenia Slovenia s population: 2 million Incidence
More informationTime to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests
Accepted Manuscript Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests Yi-Chia Lee, MD, PhD, Jean Ching-Yuan Fann, PhD, Tsung-Hsien Chiang,
More informationSocioeconomic and ethnic inequalities in organized colorectal cancer screening participation
Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation C.M. de Klerk 1, S. Gupta 2, E. Dekker 1, M.L. Essink-Bot 3 1) Department of Gastroenterology and Hepatology,
More informationFrequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema
Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To
More informationPost-polypectomy follow-up after. removal of colorectal neoplasia
Post-polypectomy follow-up after removal of colorectal neoplasia Post-polypectomy endoscopic surveillance For each type of polyp BENEFIT 1. What is the risk of CRC/Adv. Neo. (AN) w/out surveillance?
More information11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist
Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Anil K Sharma MD FACP Professor of Clinical Medicine, University of Rochester Chief of Gastroenterology,
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationThe effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial
Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an
More informationBowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care
Bowel cancer risk in the under 50s Greg Rubin Professor of General Practice and Primary Care Prevalence of GI problems in the consulting population Thompson et al, Gut 2000 Number of patients % of patients
More informationScreening for colorectal cancer. Stuart Taylor Consultant Radiologist University College Hospital
Screening for colorectal cancer Stuart Taylor Consultant Radiologist University College Hospital Topics Rationale for screening Screening methods CTC (+CAD) as a screening tool Epidemiology 943,000 cases
More informationFinancial Disclosers
Slide 1 Colorectal Cancer Screening Jason Hemming, MD NESGNA November 15, 2014 Slide 2 Bio Slide 3 Financial Disclosers I have no actual or potential conflict of interest relation to this presentation
More informationDebate: General surveillance/screening for colon cancer in a resource constrained environment is imperative
Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the
More informationColonoscopy Quality Data
Colonoscopy Quality Data www.dhsgi.com Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. In 2016, there are expected to
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Colonoscopy requirements of population screening for colorectal cancer in New Zealand Terri Green, Ann Richardson, Susan Parry
More informationColorectal Cancer Screening. Paul Berg MD
Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order
More informationCENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female.
A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC) 5 Key Messages Screening reduces mortality from CRC All persons aged 50 years and older should begin regular screening High-risk
More informationBowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria
Bowel Cancer Prevention and Screening Harriet Wynne, Cancer Council Victoria New cases and deaths for the Victoria population in 2013 Thursfield V, et al. Cancer in Victoria: Statistics & trends 2013.
More informationRx Only. Detecting Cancer In Blood.
Epi procolon is an FDA-approved blood test for colorectal cancer screening for patients who are unwilling or unable to be screened by recommended methods. Rx Only Intended Use, Contraindications, Warnings,
More informationThe choice of methods for Colorectal Cancer Screening; The Dutch experience
The choice of methods for Colorectal Cancer Screening; The Dutch experience Monique van Leerdam, Gastroenterologist, NKI-AVL, Amsterdam The Netherlands Colorectal cancer CRC 2 nd cause of cancer related
More informationPATIENT BROCHURE. 441 Charmany Dr 1 Madison WI, RX Only
PATIENT BROCHURE 441 Charmany Dr 1 Madison WI, 53719 844-870- 8870 Cologuard colorectal cancer screening test is a registered trademark of Exact Sciences Corporation. Indications for Use Cologuard is intended
More informationAdding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample
Adding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample Victorine H. Roos, Frank G.J. Kallenberg, Manon van der Vlugt, Evelien J.C. Bongers,
More informationHow to Screen a patient with a Family History of Adenoma(s)
How to Screen a patient with a Family History of Adenoma(s) CDDW Banff 3-5-17 David Lieberman MD Chief, Division of Gastroenterology and Hepatology Oregon Health and Science University Disclosures 2016
More informationSymptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study
Herrero et al. BMC Gastroenterology (2018) 18:155 https://doi.org/10.1186/s12876-018-0887-7 RESEARCH ARTICLE Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection
More informationRisk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s
Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s Hospital GI inflammation IBD Group QIMR Berghofer Medical
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationC olorectal cancer (CRC) is the second most common
CANCER Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial J H Scholefield, S Moss, F Sufi, C M Mangham, J D Hardcastle... See end of
More informationT. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1
The International Journal of Biological Markers, Vol. 21 no. 3, pp. 157-161 2006 Wichtig Editore Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold
More informationLessons learnt from cancer screening programmes as an example for establishing the Czech National Coordination Centre
Czech National Coordination Centre for Prevention of Serious Diseases CZ.03.2.63/0.0/0.0/15_039/0006904 Lessons learnt from cancer screening programmes as an example for establishing the Czech National
More information